Literature DB >> 189368

Cancer chemotherapy: its role in the treatment strategy of hematologic malignancies and solid tumors.

A Clarysse, Y Kenis, G Mathe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 189368

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN： 0080-0015


× No keyword cloud information.
  7 in total

1.  Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin. I. Oncostatic effects in mice.

Authors:  M Hayat; C Bourut; E Chenu; J L Montero; J L Imbach; J S MacDonald; G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  The multiplication of analogs, the best strategy for rapid extension of the oncostatic arsenal. How can they be compared experimentally?

Authors:  G Mathé; C Jasmin
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas.

Authors:  M Bayssas; J Gouveia; P Ribaud; M Musset; F de Vassal; J L Pico; L de Luca; J L Misset; D Machover; D Belpomme; L Schwarzenberg; C Jasmin; M Hayat; G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Chemotherapy, a double agent in respect of immune functions.

Authors:  G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

5.  Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder tumors.

Authors:  I Fukui; H Sekine; K Kihara; T Yamada; T Kawai; M Washizuka; D Ishiwata; K Oka; K Hosoda; S Ikegami
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. An oncostatic anthracyclin that is rarely cardiotoxic and induces no alopecia.

Authors:  G Mathé; M Bayssas; J Gouveia; D Dantchev; P Ribaud; D Machover; J L Misset; L Schwarzenberg; C Jasmin; M Hayat
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

7.  Preliminary results of chemo-radiotherapy followed or not by active immunotherapy of stage III and IV lymphosarcoma and reticulosarcoma. Correlation of the results with WHO categorisation.

Authors:  J L Misset; G Mathé; M Tubiana; B Caillou; F de Vassal; P Pouillart; M Gil; C Tentas; M Hayat; L Schwarzenberg; C Jasmin; M Delgado; D Machover; P Ribaud; M Musset
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.